Personalizable dosage form

• US 20100068275A1
• Filed: 09/16/2008
• Published: 03/18/2010
• Est. Priority Date: 09/16/2008
• Status: Abandoned Application

• Current Assignee: The Invention Science Fund I, L.L.C. (Intellectual Ventures LLC)
• Original Assignee: Searete LLC (Intellectual Ventures LLC)
• Inventors: Ishikawa, Muriel Y., Boyden, Edward S., Wood, Lowell L. JR., Rivet, Dennis J., Hyde, Roderick A., Sweeney, Elizabeth A., Wood, Victoria Y.H., Bangera, Mahalaxmi Gita
• Application Number:
  US12/284,014
• Publication Number:
  US 20100068275A1
• Time in Patent Office: Days
• US Class Current: 424/484
• CPC Class Codes: A61K 9/0009 involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis microelectromechanical systems A61K9/0097
• CPC Class Codes: A61K 9/0068 Rumen, e.g. rumen bolus

Abstract

Provided embodiments include a final dosage form, an article of manufacture, and a method. A method of fulfilling a request specifying a dose of a medicament for an individual animal includes choosing pursuant to the request an instance of a final dosage form that includes the medicament. The method also includes selecting a stimulus effective to change a medicament-release state of a release element of the final dosage form. The method further includes initiating an ex vivo exposure of the release element of the chosen instance of the final dosage form to the selected stimulus. The method further includes the release element configured in a first medicament-release state and changeable to a second medicament-release state upon an ex vivo exposure to a stimulus.

Claims

1. An article of manufacture comprising:

a final dosage form including;

a medicament;

an outer layer;

a release element configured in a first medicament-release state and modifiable to a second medicament-release state upon an ex vivo exposure to an actuation-stimulus; and

a chamber at least substantially within the outer layer and configured to carry the medicament; and

an instruction for preparation of the final dosage form for an administration to an animal by an ex vivo exposure of the release element of the final dosage form to the actuation-stimulus.

2. The article of manufacture of claim 1, wherein the instruction for preparation of the final dosage form for an efficacious administration to an animal by an ex vivo exposure of the release element of the final dosage form to the actuation-stimulus includes:

an instruction that includes at least one of an information indicating an actuation-stimulus type, an actuation-stimulus wavelength, an actuation-stimulus intensity, an actuation-stimulus duration, a spatial distribution of the stimulus relative to the final dosage form, a target-value for an exposure indicator, or a combination thereof.

3. The article of manufacture of claim 1, wherein the instruction for preparation of the final dosage form for an efficacious administration to an animal by an ex vivo exposure of the release element of the final dosage form to the actuation-stimulus includes:

instruction for preparation of the final dosage form for an efficacious administration to an animal by an ex vivo exposure of the release element of the final dosage form to the actuation-stimulus, the instruction presented by at least one of a label on said article of manufacture, a package insert, or an address to electronic content.

4. The article of manufacture of claim 1, wherein the instruction for preparation of the final dosage form for an efficacious administration to an animal by an ex vivo exposure of the release element of the final dosage form to the actuation-stimulus includes:

instruction for preparation of the final dosage form for an efficacious administration to an animal by a human-initiated ex vivo exposure of the release element of the final dosage form to the actuation-stimulus.

5. The article of manufacture of claim 1, wherein the final dosage form further includes:

an indicator element configured to indicate an exposure of the release element to the stimulus.

6. The article of manufacture of claim 5, wherein the instruction for preparation of the final dosage form for an efficacious administration to an animal by an ex vivo exposure of the release element of the final dosage form to the actuation-stimulus includes:

an instruction that includes an information indicating an expected value of the indicator element.

7. The article of manufacture of claim 1, wherein the final dosage form further includes:

a containment element configured to retain the medicament within the final dosage form until the final dosage form is introduced into the animal.

8. A method of modulating a medicament-release characteristic of a final dosage form, the method comprising:

irradiating a release element of the final dosage form ex vivo with a non-ionizing radiation;

wherein the final dosage form includes;

a medicament;

an outer layer;

a release element configured in a first medicament-release state and modifiable to a second medicament-release state upon an ex vivo exposure to a non-ionizing radiation; and

a chamber at least substantially within the outer layer and configured to carry the medicament.

9. The method of claim 8, wherein the irradiating a release element of the final dosage form ex vivo with a non-ionizing radiation includes:

irradiating in response to a human-initiated activation a release element of the final dosage form ex vivo with a non-ionizing radiation.

10. The method of claim 8, wherein the irradiating a release element of the final dosage form ex vivo with a non-ionizing radiation includes:

automatically initiating an ex vivo irradiation with a non-ionizing radiation a release element of the final dosage form.

11. The method of claim 8, wherein the irradiating a release element of the final dosage form ex vivo with a non-ionizing radiation includes:

irradiating a first release element of the final dosage form ex vivo with a non-ionizing radiation without irradiating a second release element of the final dosage form with the non-ionizing radiation.

12. The method of claim 8, wherein the irradiating a release element of the final dosage form ex vivo with a non-ionizing radiation includes:

irradiating a first release element of the final dosage form ex vivo with a non-ionizing radiation without irradiating a second release element of the final dosage form with the non-ionizing radiation, the first release element associated with a first chamber carrying a first instance of the medicament, and the second release element associated with a second chamber carrying a second instance of the medicament.

13. The method of claim 8, wherein the ex vivo irradiation of at least one release element of the final dosage form with a non-ionizing radiation includes:

irradiating a first release element of the final dosage form ex vivo with a non-ionizing radiation without irradiating a second release element of the final dosage form with the non-ionizing radiation, the first release element associated with a first chamber carrying a first medicament, and the second release element associated with a second chamber carrying a second medicament.

14. The method of claim 8, wherein the final dosage form further includes:

a containment element configured to retain the medicament within the final dosage form until the final dosage form is introduced into the animal.

15. A method of fulfilling a request specifying a dose of a medicament for an individual animal, the method comprising:

choosing pursuant to the request an instance of a final dosage form that includes the medicament;

selecting a stimulus configured to change a medicament-release state of a release element of the final dosage form; and

initiating an ex vivo exposure of the release element of the chosen instance of the final dosage form to the selected stimulus;

wherein the final dosage form includes;

the medicament;

an outer layer;

the release element configured in a first medicament-release state and changeable to a second medicament-release state upon an ex vivo exposure to a stimulus; and

a chamber at least substantially within the outer layer and configured to carry the medicament.

16. The method of claim 15, further comprising:

receiving the request specifying an efficacious medicament dose for an individual animal.

17. The method of claim 15, wherein the choosing pursuant to the request an instance of a final dosage form that includes the medicament includes:

choosing pursuant to at least one of an order, and a prescription an instance of a final dosage form that includes the medicament.

18. The method of claim 15, wherein the choosing pursuant to the request an instance of a final dosage form that includes the medicament includes:

at least one of physically or manually choosing pursuant to the request an instance of a final dosage form that includes the medicament.

19. The method of claim 15, wherein the selecting a stimulus configured to change a medicament-release state of a release element of the final dosage form includes:

selecting a stimulus having an attribute indicated by at least one of a manufacturer of the final dosage form, an instruction packaged with the dosage form, an electronically published content, and a printed publication as effective to change a medicament-release state of a release element of the final dosage form.

20. The method of claim 15, wherein the selecting a stimulus configured to change a medicament-release state of a release element of the final dosage form includes:

selecting a stimulus configured by at least one of a type, amount, level, wavelength, spectrum, waveform, duration, spatial distribution, or pulse attribute to change a medicament-release state of a release element of the final dosage form.

21. The method of claim 15, wherein the selecting a stimulus configured to change a medicament-release state of a release element of the final dosage form includes:

selecting a stimulus configured to change a medicament-release state of a release element of the final dosage form and to make the request-specified dose of medicament dose bioavailable by the final dosage form.

22. The method of claim 15, wherein the initiating an ex vivo exposure of the release element of the chosen instance of the final dosage form to the selected stimulus includes:

changing a medicament-release state of the release element of the chosen instance of the final dosage form by initiating an ex vivo exposure of the release element of the chosen instance of the final dosage form to the selected stimulus.

23. The method of claim 15, wherein the initiating an ex vivo exposure of the release element of the chosen instance of the final dosage form to the selected stimulus includes:

preparing a bioavailable dose of the medicament of the final dosage form in fulfillment of the request by initiating an ex vivo exposure of the release element of the chosen instance of the final dosage form to the selected stimulus.

24. The method of claim 15, wherein the initiating an ex vivo exposure of the release element of the chosen instance of the final dosage form to the selected stimulus includes:

initiating an ex vivo exposure of the release element of the chosen instance of the final dosage form to the selected stimulus in fulfillment of the request.

25. The method of claim 15, further comprising:

verifying the ex vivo exposure of the release element of the chosen instance of the final dosage form to the selected stimulus.

26. The method of claim 25, wherein the verifying the ex vivo exposure of the release element of the chosen instance of the final dosage form to the selected stimulus includes:

optically verifying the ex vivo exposure of the release element of the chosen instance of the final dosage form to the selected stimulus.

27. The method of claim 25, wherein the verifying the ex vivo exposure of the release element of the chosen instance of the final dosage form to the selected stimulus includes:

electronically verifying the ex vivo exposure of the release element of the chosen instance of the final dosage form to the selected stimulus.

28. The method of claim 15, wherein the final dosage form further includes a containment element configured to retain the medicament within the final dosage form until when the final dosage form is introduced into the animal.

29. The method of claim 15, further comprising:

dispensing the chosen instance of the final dosage form after the ex vivo exposure of the release element of the chosen instance of the final dosage form to the selected stimulus as described above.

30. The method of claim 29, wherein the dispensing the ex vivo exposed instance of the final dosage form for administration to the individual animal includes:

dispensing the ex vivo exposed instance of the final dosage form in a package bearing an identifier of the individual animal.